Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
CarMax Auto Owner Trust 2026-4 Capital Raise of $1.33B
CarMax Auto Owner Trust 2026-4 completed the issuance of $1,333,122,000 in asset-backed notes across multiple classes (A-1 through D). The transaction involved the transfer of motor vehicle retail installment sale contracts from CarMax Business Services to the trust to serve as collateral for the securities.
Abbott Laboratories announced its intention to separate its global Nutrition business into an independent, publicly traded company via a tax-free distribution to shareholders. The new entity will be a global leader in healthy nutrition with approximately $8.5 billion in annual sales and a portfolio including brands like Similac, Ensure, and PediaSure. The separation is expected to be completed by the end of 2027.
“As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market. Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition, and it will be better positioned as an independent company to more effectively direct its strategic resources across its priorities.”
Robert B. Ford, chairman and chief executive officer, Abbott
Smith & Wesson Brands Signs $165M M&A Deal with Savage Arms
Smith & Wesson Brands, Inc. acquired Savage Arms from JDH Capital for an adjusted transaction value of approximately $164.9 million. The consideration consisted of $42.4 million in cash and 8,993,968 shares of common stock, making JDH Capital the company's largest stockholder. The deal meaningfully expands Smith & Wesson's presence in the hunting and bolt-action rifle categories.
Value
$165M
Counterparty
Savage Arms
“The acquisition of Savage is a transformative step for Smith & Wesson and an important milestone in our strategy to be the undisputed market leader in the firearm industry. Savage’s brand heritage, culture, and longstanding reputation for performance and innovation align closely with our own, and the business meaningfully expands our presence in the hunting category. By bringing these two companies together, we have created a broader, stronger platform with significant opportunities to better serve our customers, accelerate innovation, realize operating efficiencies and drive long-term value for our stockholders.”
Mark Smith, President and Chief Executive Officer of Smith & Wesson
Consolidated Water Co M&A Deal with Honolulu Board of Water Supply
Consolidated Water provided a status and timeline update for its Kalaeloa seawater desalination project in Hawaii, noting that construction is now expected to begin in the first half of 2027 due to permitting delays. The project recently received key approvals from the State Historic Preservation Division and the Hawaii Department of Health, and the Honolulu Board of Water Supply has granted schedule extensions and authorized $6 million for long-lead equipment procurement.
Elmet Group Partnership with Blue Moon Metals Inc.
Elmet Group Co. entered into a strategic partnership with Blue Moon Metals Inc. involving an equity investment and board representation to support the development of the Springer Tungsten Complex in Nevada. Elmet purchased 3,500,000 units at CAD 10.00 per unit, with each unit consisting of one common share and one purchase warrant, and entered into an Investor Rights Agreement granting Elmet the right to nominate one director to the Blue Moon Board.
NextTrip Partnership with The Travel Agent Next Door Inc.
NextTrip entered into a joint venture agreement with The Travel Agent Next Door (TTAND) to launch JOURNYGO Travel in Canada. The partnership combines NextTrip's JOURNY TV media content with TTAND's network of 1,850 agents to provide travel booking and fulfillment, with NextTrip receiving a share of booking commissions.
Imunon Divestiture to VoxelDox Therapeutics, Inc. for $16.5M
Imunon entered into an asset purchase agreement to sell its ThermoDox assets to VoxelDox Therapeutics, which intends to develop the drug for glioblastoma. Imunon will receive a 4.76% equity stake in VoxelDox, up to $16.5 million in clinical and regulatory milestone payments, and royalties on future net sales. The closing is contingent on VoxelDox raising at least $2.5 million in financing.
UDR, Inc. announced the formation of a long-term strategic joint venture with Apollo involving a diversified portfolio of 19 apartment communities totaling 7,059 homes. The portfolio contributed by UDR is valued at approximately $2.0 billion, and the company simultaneously raised its full-year 2026 guidance for Net Income and FFOA.
Getty Images Holdings, Inc. and several subsidiaries filed voluntary petitions for Chapter 11 bankruptcy protection in the District of Delaware to implement a prepackaged reorganization plan. The restructuring is supported by a previously announced agreement with majority shareholders and lenders to recapitalize the company's funded indebtedness. The company has filed first-day motions to continue ordinary operations, including payments to employees, vendors, and content contributors.
Cencora Signs $2.4B M&A Deal with American Oncology Network, Inc.
Cencora has signed a definitive agreement to acquire American Oncology Network (AON) for an enterprise value of $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The acquisition expands Cencora's oncology management services organization (MSO) platform by adding a network of over 350 oncology providers across 21 states.
Pine Tree Acquisition Corp. announced that holders of its units from its initial public offering may elect to separately trade the underlying Class A ordinary shares and rights starting October 23, 2026. The separated securities will list on Nasdaq under the symbols 'PAXG' and 'PAXGR', while unseparated units will continue to trade under 'PAXGU'.
Soluna Holdings Partnership with Applied Digital Corporation
Soluna Holdings has entered into a definitive agreement to form a jointly owned company with Applied Digital Corporation to develop a 50 MW AI and HPC data center at Project Dorothy 3 in Texas. Applied Digital will hold a 51% interest and provide capital, while Soluna will hold 49% and contribute land and project assets. Additionally, ChronoScale Holdings has signed a letter of intent to lease the planned facility under a triple-net lease arrangement.
Worthington Steel issued a status update regarding its pending Domination and Profit and Loss Transfer Agreement (DPLTA) with Klöckner & Co SE ahead of an extraordinary general meeting. The company stated that if the DPLTA vote does not achieve the required 75% majority, it will not pursue another vote for at least one year.
Roivant and its subsidiary Priovant Therapeutics announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). The drug met its primary and all key secondary endpoints in two identical trials, demonstrating a median time to treatment failure of over 48 weeks compared to 12 weeks for placebo, and the company plans to file a supplemental New Drug Application (sNDA) in the first half of 2027.
Genprex highlighted peer-reviewed preclinical research published in Mechanisms of Ageing and Development regarding the TUSC2 gene, which is the therapeutic component of its REQORSA oncology program. The study found that TUSC2 deficiency in mice leads to mitochondrial dysfunction and protein homeostasis collapse in the brain, with human datasets showing TUSC2 expression also declines with age and Alzheimer's disease. While exploratory, the findings suggest TUSC2 plays a foundational role in brain health beyond its established role in cancer treatment.
Vivos Therapeutics received a letter from Nasdaq confirming that the company has regained compliance with the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1). The compliance was achieved following a transaction involving the issuance of Series C Convertible Preferred Stock, which is expected to increase stockholders' equity by more than $10 million. The company must continue to evidence compliance in its next periodic report to avoid potential delisting.
Apex Tech Acquisition Signs $3.5B M&A Deal with Korai Flix, Inc.
APEX Tech Acquisition Inc. (a SPAC) has entered into a definitive merger agreement to acquire Korai Flix, Inc., an AI-powered interactive online entertainment platform, in a deal valuing Korai at $3.5 billion on a pre-money equity basis. Upon closing, the combined entity will be renamed Krflix Group, Inc. and is expected to list on the NYSE. The transaction is projected to close in the first quarter of 2027, subject to shareholder and regulatory approvals.
Nova Minerals Signs $3.5B M&A Deal with Korai Flix Inc.
APEX Tech Acquisition Inc. (NYSE: TRAD) has entered into a definitive merger agreement to acquire Korai Flix Inc., an AI-powered interactive online entertainment platform, in a deal valuing Korai at $3.5 billion on a pre-money equity basis. Upon closing, expected in Q1 2027, the combined company will be renamed Krflix Group Inc. and is expected to list on the NYSE.
Silicon Valley Acquisition Signs $5M M&A Deal with EigenQ, Inc.
Silicon Valley Acquisition Corp. (SVAQ) provided an update on its pending merger with EigenQ, Inc., specifically announcing a subordinated unsecured note financing. SVAQ and EigenQ entered into an agreement with an investor for the issuance of up to $5 million in promissory notes and warrants to support the transaction. This financing is part of the broader capital structure required to complete the previously announced business combination.
Nuburu, Inc. completed the acquisition of an additional 67.1% interest in Tekne S.p.A. for a fixed purchase price of €5.2 million, bringing its total ownership to 70%. The deal includes a €20 million cash earn-out payable through 2036 based on 5% of annual revenues with a guaranteed annual minimum of €2 million. As part of the transaction, Nuburu waived approximately €29.7 million in receivables owed by Tekne as a capital contribution to recapitalize the entity.
Cenntro Inc. filed an amendment to a previous 8-K to include a legal opinion from Wendot Law Group regarding its at-the-market (ATM) equity offering program. The filing serves as a routine administrative update to support the company's existing registration statement for the sale of common stock.
Olenox Industries Signs $22M M&A Deal with IPD Industries, Inc. and Wildboy Holdings, Ltd.
Olenox Industries completed the acquisition of IPD Industries and Wildboy Holdings for $22 million in a mix of common stock, Series F preferred stock, and cash. The deal adds natural gas processing assets in British Columbia and a 100 MW power-development platform in Texas to support the company's gas-to-power-to-compute strategy for AI and data centers.
Value
$22M
Counterparty
IPD Industries, Inc. and Wildboy Holdings, Ltd.
“Power is becoming one of the defining constraints on the growth of artificial intelligence and digital infrastructure. With these acquisitions, we are building a platform that starts with the energy itself. Wildboy gives us control of natural gas resources, and IPD gives us a registered foundation for developing power generation in West Texas. Together, they position us to capture more value across the chain -- from gas to electricity to computing.”
Michael McLaren, Chairman and Chief Executive Officer of Olenox
Grown Rogue International Signs $743K M&A Deal with ABCO Garden State, LLC
Grown Rogue International Inc. has exercised its second option to acquire an additional 26% ownership interest in its New Jersey subsidiary, ABCO Garden State, LLC, for approximately $0.743 million. This transaction increases the company's total ownership stake to 70% and grants it majority control of ABCO's board of directors following approval from the New Jersey Cannabis Regulatory Commission.
Value
$743K
Counterparty
ABCO Garden State, LLC
“We're very pleased with how New Jersey is performing, and this step is largely a formality as we continue to focus on completing our canopy expansion and growing the business.”
Obie Strickler, CEO of Grown Rogue
“We remain on schedule to have construction of Phase II substantially complete by the end of 2026, bringing total New Jersey flowering canopy to approximately 16,000 square feet, with the additional capacity ramping into 2027.”
Neptune Insurance delivered record Q3 results with 34% revenue growth and significant margin expansion, driven by AI-powered agent productivity and a capital-light model despite headwinds in housing and weather.
Aspire-Lakewood Holdings Signs $30M M&A Deal with Dura Driver Control Systems
Aspire-Lakewood Holdings completed the acquisition of Dura Driver Control Systems (DCS) for a purchase price of $30 million. In connection with the closing, the company entered into a five-year management services agreement with Lakewood Capital, LLC, which includes a $0.5 million closing fee and a 15% equity stake in the acquired entity for the service provider.
Dream Finders Homes Signs $878M M&A Deal with Beazer Homes USA, Inc.
Dream Finders Homes completed its acquisition of Beazer Homes USA, Inc. for approximately $878.4 million in cash, creating the sixth-largest U.S. homebuilder. Beazer shareholders received $33.50 per share, and the company's stock has been delisted from the NYSE. The transaction expands Dream Finders' footprint into 26 of the top 50 MSAs and is expected to generate over $100 million in annual cost synergies.
Value
$878M
Counterparty
Beazer Homes USA, Inc.
“Today, Beazer’s teams officially join ours, and the real work begins. We are closing this transaction in a challenging housing environment, and we are clear-eyed about that. But we believe this acquisition is transformative for Dream Finders. It makes us the nation’s sixth-largest homebuilder and brings us into new markets where Beazer was already proficient.”
Patrick Zalupski, Founder, CEO, and Co-Chairman of Dream Finders
“With the acquisition completed, the Board’s focus now turns to disciplined execution. This combination is built to perform throughout the housing market cycle. We continue to expect over $100 million of annual run-rate cost synergies and double-digit percentage EPS accretion in year one, while expanding our financial services platform and preserving the asset-light model that underpins our returns.”
Sports Entertainment Gaming Global Nasdaq/NYSE Compliance Notice
Sports Entertainment Gaming Global Corp received a Nasdaq Staff Determination letter on October 14, 2026, notifying the company of a delisting threat due to its failure to file its Q2 2026 Form 10-Q. The company has requested a hearing before the Nasdaq Hearings Panel to stay the suspension of its common stock and warrants and present a plan to regain compliance.
DoubleVerify Holdings M&A Deal with Neptune BidCo US Inc.
DoubleVerify Holdings provided a status update on its pending acquisition by Neptune BidCo US Inc. (a parent company of Nielsen). The filing discloses that the merger received regulatory clearance from the German Federal Cartel Office on October 5, 2026, and supplements the company's definitive proxy statement with updated antitrust filing timelines for other jurisdictions.
ESG Inc. entered into a Control Share Purchase and Transfer Agreement where DCG China Limited will sell 9,641,110 shares (approximately 61.8% of the company) to BevPoint Capital LP for $250,000. The deal represents a change of control that will result in the resignation of incumbent officers and directors and the appointment of BevPoint-designated successors upon closing. The agreement also contemplates a future business combination involving BevPoint's operating business.
Surrozen completed the second and final tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by the achievement of a milestone involving FDA clearance of the IND application for SZN-8141. The funding is expected to provide a cash runway into 2029 to advance the company's ophthalmology pipeline through clinical milestones.
Value
$95.1M
“The completion of this financing marks an important milestone for Surrozen, significantly strengthening our balance sheet and providing the resources to advance our ophthalmology pipeline through multiple important clinical milestones.”
Craig Parker, President and Chief Executive Officer
“With expected cash runway into 2029, we are well positioned to advance SZN-8141 into the DUET Phase 1b/2a study and initiate clinical development of SZN-8143, while maintaining a disciplined approach to capital allocation.”
Craig Parker, President and Chief Executive Officer